

PLURISTEM THERAPEUTICS INC  
Form 4  
September 24, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BEN-YORAM ISRAEL

2. Issuer Name and Ticker or Trading Symbol  
PLURISTEM THERAPEUTICS INC [PSTI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
09/21/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)

24 BARKAN STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

RISHON LEZION, L3 75436

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |   |
| Common Stock                    | 09/21/2015                           |  | S(1)(2)                        |   | 30,000  | D  | \$ 2.1 176,056  |
| Common Stock                    | 09/21/2015                           |  | P(1)                           |   | 12,300  | A  | \$ 2.07 188,356                                       |
| Common Stock                    | 09/21/2015                           |  | P(1)                           |   | 3,200   | A  | \$ 2.08 191,556                                       |
| Common Stock                    | 09/21/2015                           |  | P(1)                           |   | 100   | A  | \$ 2.09 191,656                                       |
| Common Stock                    | 09/21/2015                           |  | P(1)                           |   | 7,200   | A  | \$ 2.1 198,856  |

Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 4

|              |            |                  |       |   |         |         |   |                   |
|--------------|------------|------------------|-------|---|---------|---------|---|-------------------|
| Common Stock | 09/21/2015 | P <sup>(1)</sup> | 3,900 | A | \$ 2.11 | 202,756 | D |                   |
| Common Stock | 09/21/2015 | P <sup>(1)</sup> | 3,300 | A | \$ 2.14 | 206,056 | D |                   |
| Common Stock |            |                  |       |   |         | 162,750 | I | By Eshed Dash Ltd |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |

## Reporting Owners

| Reporting Owner Name / Address                                  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| BEN-YORAM ISRAEL<br>24 BARKAN STREET<br>RISHON LEZION, L3 75436 |               | X         |         |       |

## Signatures

/s/ Israel  
Ben-Yoram 09/24/2015

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The reporting person's sale of 30,000 shares of PSTI common stock reported herein is matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of 30,000 shares of PSTI common stock reported herein. The reporting person
- (1) has agreed to pay to PSTI, upon settlement of the sale, \$323, representing the full amount of the profit realized in connection with the short-swing transaction.
  - (2) Private sale in New Israeli Shekels (NIS) for a per share price of NIS 8.12, which per share price has been reported on this Form 4 in U.S. dollars based on an exchange rate of NIS 3.863 per U.S. dollar.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.